antivirals Flashcards
HIV fusion inhibition
attachment: maravirocpenetration: enfuvirtide
HIV inTEGRAse inhibition
doluTEGRAvir, elviTEGRAvir, ralTEGRAvir
HIV protease inhibition
atazanavir, darunavir, fosamprenavir, indinavir, lopinavir, ritonavir, saquinavir
HIV reverse transcriptase inhibition
NRTIS, NNRTI
NRTIs
abacavir, didanosine, emtricitabine, lamivudine, stavudine, tenofovir, zidovudine
NNRTIs
delaviridine, efavirenz, nevirapine
HBV, HCV protein synthesis inhibition
INF-a (binds via PKR)
uncoating (influenza)
amantadine, rimantadine(no longer used, high resistance)
Guanosine analogs
acyclovir (HSV, VZV)Ganciclovir (CMV)
viral DNA polymerase inhibitors
cidofovir (HSV)foscarnet (CMV)
guanine nucleoside synthesis inhibitor
ribavirin (RSV, HCV)
release of progeny inhibitors
neuraminidase inhibitors (Oseltamivir, Zanamivir) in flu A,B
Ganciclovir MOA
5’-monophosphate formed by CMV viral kinase. Guanosine analog. Triphosphate formed by cellular kinases. preferentially inhibits viral DNA polymerase
Ganciclovir use
CMV, esp. in IC pts.
Valganciclovir, prodrug of ganciclovir, has better oral bioavailability
Ganciclovir ADR
bone marrow suppression (leukopenia, neutropenia, thrombocytopenia); renal toxicity
more toxic to host than acyclovir
Ganciclovir resistance
mutated viral kinase
Foscarnet MOA
Viral DNA/RNA polymerase inhibitor and HIV reverse transcriptase inhibitor.
Binds to pyrophosphate-binding site of enzyme.
*Does not require any kinase activation
Foscarnet use
CMV retinitis in IC patients when ganciclovir fails; acyclovir-resistant HSV
Foscarnet ADR
nephrotoxicity, electrolyte abnormalities lead to seizures
Foscarnet Mech of resistance
mutated DNA polymerase
Cidofovir MOA
preferentially inhibits viral DNA polymerase. Does not require phosphorylation by viral kinase
Cidofovir use
CMV retinitis in IC patients;
acyclovir-resistant HSV.
Long-half life
Cidofovir ADR
nephrotoxicity (coadmin w/ probenecid and IV saline to dec)
HIV triple therapy
2 NRTIs and preferably an integrase inhibitor
NRTIs MOA (HIV)
competitively inhibit nucleotide binding to reverse transcriptase and terminate the DNA chain (lack 3’ OH group)
NRTI make-up
nucleoSides that need to be phosphorylated to be active except Tenofovir (nucleoTide)
Zidovudine (ZDV) use
general prophylaxis and during pregnancy to dec risk of fetal transmission
NRTI toxicity
bone marrow suppression, peripheral neuropathy
NRTI bone marrow suppression TX
granulocyte colony-stimulating factor and EPO
NRTI nucleoside ADR
lactic acidosis
ZDV ADR
anemia
didanosine ADR
pancreatitis
Abacavir contraindication
pt has HLA-B*5701 mutation
NNRTIs MOA (HIV)
bind to reverse transcriptase at site different from NRTIs. Do not require phosphorylation to be active or compete with nucleotides
NNRTI ADR
rash and hepatotoxicity
NNRTIs contraindicated in pregnancy
delavirdine and efavirenz
Efavirenz ADR
vivid dreams and CNS sx
Protease Inhibitors (-navir) MOA (HIV)
assembly of virions depends on HIV-1 protease (pol gene), which cleaves polypeptide products of HIV mRNA into their functional parts. *thus protease inhibitors prevent maturation of new viruses
Ritonavir use
“boosts” other drug concentrations by inhibiting p450
Protease inhibitor ADR
hyperglycemia, GI intolerance, lipodystrophy (Cushing-like syndrome)
Indinavir ADR
nephropathy, hematuria
what drug should never be used with protease inhibitors?
Rifampin (potent CYP/UGT inducer) bc it decreases protease inhibitor concentration
integrase inhibitors MOA
inhibits HIV genome integration into host cell chromosome by reversibly inhibiting HIV integrase
integrase inhibitors ADR
inc. creatine kinase
Enfuvirtide MOA
fusion inhibitor
binds gp41, inhibiting viral entry
Enfuvirtide ADR
skin rxn at injection site
Maraviroc MOA
binds CCR-5 on surface of T cells/monocytes, inhibiting interaction with gp120
Interferons MOA
glycoproteins norm synthesized by virus-infected cells, exhibiting wide range of antiviral and antitumoral properties
INF-a use
chronic HBV and HCV; Kaposi sarcoma; hairy cell leukemia; condyloma acuminatum; renal cell carcinoma; malignant melanoma
INF-b use
multiple sclerosis
INF-y use
chronic granulomatous disease
interferons ADR
flu-like symptoms, depression, neutropenia, myopathy
Ribavirin (HCV) MOA
inhibits synthesis of guanine nucleotides by competitively inhibiting inosine monophosphate dehydrogenase
Ribavirin use
chronic HCV, RSV
Ribavirin ADR
hemolytic anemia, severe teratogen
RSV tx in kids
palivizumab
Sofosbuvir MOA
inhibits HCV RNA-dependent RNA polymerase acting asa chain terminator
Sofosbuvir use
chronic HCV in combo w/ ribavirin
don’t use as monotherapy
Sofosbuvir ADR
fatigue, HA, nausea
Simeprevir MOA
HCV protease inhibitor; prevents viral replication
Simeprevir use
chronic HCV in combo w/ ledipasvir (NS5A inhibitor)
don’t use as monotherapy
Simeprevir ADR
photosensitivity rxns, rash